Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant ...